NeuroSigma, Inc., a California-based medical device company, today announced the launch of www.monarch-etns.com, its dedicated website for the Monarch™ eTNSTM System. The new site provides a comprehensive resource for those in the European Union and Canada who are considering use of the non-invasive Monarch system to treat their epilepsy and depression in conjunction with their existing drug treatment program. The therapeutic neuromodulation system is not yet approved for use in the United States.
Visitors to the site will find information on:
-
How the Monarch system works
-
How to start a conversation with your doctor about the Monarch system
-
Important information about epilepsy and depression, especially when those conditions are resistant to medications
-
Pricing and how to order the system if you live in the European Union or Canada
Patients and physicians who want more in-depth knowledge will find:
-
Peer-reviewed, published research papers on the effectiveness of the Monarch system
-
A presentation at the Royal Society of Medicine in London by Dr. Christopher DeGiorgio , one of the original inventors of the system,
-
A video interview with the Epilepsy Society showing how the Monarch is used
"Those who visit the site to learn more about the Monarch will become not only informed but also empowered to take the next step in managing their condition with this safe, easy-to-use and non-invasive system," said Ian Cook , M.D., Director of the UCLA Depression Research & Clinic Program and Chief Medical Advisor to NeuroSigma. "Patients and physicians alike can ask questions of the NeuroSigma team, share insights, and make suggestions. In this way the site will become an online home to a growing population of patients whose lives have been transformed by the Monarch system, as well as an expanding number of physicians who have tapped into its therapeutic potential for their patients," added Dr. Cook.
AI model combines speech and brain activity to diagnose depression